Clinically meaningful pivotal study results for olezarsen in sHTG presented as a late breaker at AHA Scientific Sessions

Contributed by: PR Newswire

Tags

SOBI-olezarsen

More Like This

New analysis shows Tryngolza® (olezarsen) reduced acute pancreatitis by 85% and triglycerides by 66% in severe hypertriglyceridemia

EMA validates indication extension application for Tryngolza® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)

TRYNGOLZA® (olezarsen) recommended for EU approval by CHMP for familial chylomicronemia syndrome (FCS)

Tryngolza ® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)

PR Newswire associated0

Menarini Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Efficacy, Safety and Tolerability of Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia

Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout

Positive data from phase 2 NOBLE study of pegcetacoplan presented as late-breaker at ERA congress

Sobi showcases new data across rare inflammatory conditions at ACR 2025